HPV 6/11, 16, 18 seroprevalence in men in two US cities

Eileen F. Dunne, Carrie Nielson, Michael E. Hagensee, Mary R. Papenfuss, Robin B. Harris, Nicholas Herrel, Jennifer Gourlie, Martha Abrahamsen, Lauri E. Markowitz, Anna R. Giuliano

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND:: A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men. METHODS:: A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays. RESULTS:: Overall, seroprevalence to HPV 16 was 12.1%, HPV 6/11 was 9.7%, and to HPV 18 was 5.4%. Seroprevalence to HPV 6/11, 16, and/or 18 was 21% and was highest among 35 to 40 year olds (48%); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking. CONCLUSIONS:: HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.

Original languageEnglish (US)
Pages (from-to)671-674
Number of pages4
JournalSexually Transmitted Diseases
Volume36
Issue number11
DOIs
StatePublished - 2009

Fingerprint

Human papillomavirus 11
Human papillomavirus 6
Seroepidemiologic Studies
Papillomavirus Vaccines
Human papillomavirus 18
Human papillomavirus 16
Serology
Epidemiology
Vaccines
Age Groups
Smoking
Odds Ratio
Confidence Intervals

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Dunne, E. F., Nielson, C., Hagensee, M. E., Papenfuss, M. R., Harris, R. B., Herrel, N., ... Giuliano, A. R. (2009). HPV 6/11, 16, 18 seroprevalence in men in two US cities. Sexually Transmitted Diseases, 36(11), 671-674. https://doi.org/10.1097/OLQ.0b013e3181bc094b

HPV 6/11, 16, 18 seroprevalence in men in two US cities. / Dunne, Eileen F.; Nielson, Carrie; Hagensee, Michael E.; Papenfuss, Mary R.; Harris, Robin B.; Herrel, Nicholas; Gourlie, Jennifer; Abrahamsen, Martha; Markowitz, Lauri E.; Giuliano, Anna R.

In: Sexually Transmitted Diseases, Vol. 36, No. 11, 2009, p. 671-674.

Research output: Contribution to journalArticle

Dunne, EF, Nielson, C, Hagensee, ME, Papenfuss, MR, Harris, RB, Herrel, N, Gourlie, J, Abrahamsen, M, Markowitz, LE & Giuliano, AR 2009, 'HPV 6/11, 16, 18 seroprevalence in men in two US cities', Sexually Transmitted Diseases, vol. 36, no. 11, pp. 671-674. https://doi.org/10.1097/OLQ.0b013e3181bc094b
Dunne, Eileen F. ; Nielson, Carrie ; Hagensee, Michael E. ; Papenfuss, Mary R. ; Harris, Robin B. ; Herrel, Nicholas ; Gourlie, Jennifer ; Abrahamsen, Martha ; Markowitz, Lauri E. ; Giuliano, Anna R. / HPV 6/11, 16, 18 seroprevalence in men in two US cities. In: Sexually Transmitted Diseases. 2009 ; Vol. 36, No. 11. pp. 671-674.
@article{b0303c48f2284ee5b95ff26b78128923,
title = "HPV 6/11, 16, 18 seroprevalence in men in two US cities",
abstract = "BACKGROUND:: A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men. METHODS:: A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays. RESULTS:: Overall, seroprevalence to HPV 16 was 12.1{\%}, HPV 6/11 was 9.7{\%}, and to HPV 18 was 5.4{\%}. Seroprevalence to HPV 6/11, 16, and/or 18 was 21{\%} and was highest among 35 to 40 year olds (48{\%}); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95{\%} confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking. CONCLUSIONS:: HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.",
author = "Dunne, {Eileen F.} and Carrie Nielson and Hagensee, {Michael E.} and Papenfuss, {Mary R.} and Harris, {Robin B.} and Nicholas Herrel and Jennifer Gourlie and Martha Abrahamsen and Markowitz, {Lauri E.} and Giuliano, {Anna R.}",
year = "2009",
doi = "10.1097/OLQ.0b013e3181bc094b",
language = "English (US)",
volume = "36",
pages = "671--674",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - HPV 6/11, 16, 18 seroprevalence in men in two US cities

AU - Dunne, Eileen F.

AU - Nielson, Carrie

AU - Hagensee, Michael E.

AU - Papenfuss, Mary R.

AU - Harris, Robin B.

AU - Herrel, Nicholas

AU - Gourlie, Jennifer

AU - Abrahamsen, Martha

AU - Markowitz, Lauri E.

AU - Giuliano, Anna R.

PY - 2009

Y1 - 2009

N2 - BACKGROUND:: A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men. METHODS:: A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays. RESULTS:: Overall, seroprevalence to HPV 16 was 12.1%, HPV 6/11 was 9.7%, and to HPV 18 was 5.4%. Seroprevalence to HPV 6/11, 16, and/or 18 was 21% and was highest among 35 to 40 year olds (48%); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking. CONCLUSIONS:: HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.

AB - BACKGROUND:: A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men. METHODS:: A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays. RESULTS:: Overall, seroprevalence to HPV 16 was 12.1%, HPV 6/11 was 9.7%, and to HPV 18 was 5.4%. Seroprevalence to HPV 6/11, 16, and/or 18 was 21% and was highest among 35 to 40 year olds (48%); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking. CONCLUSIONS:: HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.

UR - http://www.scopus.com/inward/record.url?scp=70350754603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350754603&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e3181bc094b

DO - 10.1097/OLQ.0b013e3181bc094b

M3 - Article

VL - 36

SP - 671

EP - 674

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 11

ER -